-
3 new drugs to be included in the priority review!
Time of Update: 2021-03-06
Supi Medicine's new rare disease drug Nitesinon capsules, the proposed development of adaptive disorders are: combined with tyrosine and phenylalanine dietary restrictions, for the treatment of adult and pediatric patients (at any age) hereditary HT-1.
-
AstraZenecom Fasenra Phase 3 Clinical
Time of Update: 2021-03-06
using chronic or intermittent OCS on the basis of other therapies to control their symptoms and acute exacerbation. However, frequent or long-term use of OCS can lead to serious adverse effects. PONENTE is a multi-center, open-label
-
Zhengda Sunny will take more than $3 billion varieties with Howson, Colum siege original research drugs
Time of Update: 2021-03-05
In addition to the original research manufacturers, the current domestic market has Howson, Colum two enterprises have Engele net film production approval, both enterprises' products are reported in a new classification, approved after production as if through a consistent evaluation.
-
MSD is working with Seattle Genetics on two new oncology projects
Time of Update: 2021-03-05
diversify Merck's broad portfolio and product line of oncology treatments and continue to expand and improve the lives of as many cancer patients as possible." ”（cyy123.com）
-
"One brother" easy to master, pharmacy TOP20 shuffle! 3 varieties of big rise, slow-disease medicine "over the screen", is sunny "rise"
Time of Update: 2021-03-04
varieties of attovastatin calcium tablets topped the list, chlororeta tablets for the first time on the list; first break 50 billion yuan, slow-disease drugs, the original research drug "over-screen" Figure 1:2016-2020E key city physical pharmacy
-
The fourth batch of national mining rules online interpretation! The offer was held as scheduled on 3 February
Time of Update: 2021-03-04
is worth playing with is that the fourth batch of national mining in the first year of procurement amount of less than 100 million yuan of varieties have 15, accounting for one-third of the total.
-
Pre-loss of more than 2.2 billion yuan! People's fu medicine 3 billion goodwill "thunderstorm" landed at once
Time of Update: 2021-03-04
billion yuan in 2017, and the net profit of the parent company increased from 216 million yuan in 2010 to 2.069 billion yuan in 2017, nearly 10 times in seven years. Founded in 1993 and listed on the Shanghai Stock Exchange in 1997 (600079
-
Kantai Bio's first-half net profit fell 9.84% year-on-year to raise 3 billion yuan
Time of Update: 2021-03-04
According to Pacific Securities analysis, Kantai bio-research and development of the five seedlings are expected to be listed in 2021-2022; ( Sina Pharmaceutical News )
-
(ESCC) global phase 3 clinical success: significantly extended survival!
Time of Update: 2021-03-03
issued. plans to communicate with regulators around the world about the results of the RATIONALE 302 trial and release the data at a subsequent medical conference. "We are very excited to have observed in another Phase 3 clinical trial
-
The first gist precision therapy ayvakit Phase 3 clinical failure
Time of Update: 2021-03-03
In 2017, a Phase 1 clinical study showed that the drug had a 100% disease control rate, a 100% tumor reduction rate, and a 12-month PFS rate of 78% in patients with PDGFR alpha exon 18 D842V mutant GIST.
-
-scale phase 3 clinical: prevention of moderate to severe COVID-19, total efficiency of 66%!
Time of Update: 2021-03-03
3 ENSEMBLE study aims to assess the effectiveness and safety of Jansen COVID-19 candidate vaccines in protecting moderate to severe COVID-19, with the common primary endpoint being 14 and 28 days after vaccination.
-
New Alzheimer's (AD) drug! The review period of β protein antibody aducanumab was extended by 3 months by the FDA!
Time of Update: 2021-03-03
